ID [a]	NAME	SEQUENCE	SIZE	MIC	HEMOLYSIS [b]	References (DOI)
1465	Peptide BmKn2	FIGAIARLLSKIF-NH_2	13	*S. aureus* AB94004 (6.25 μg/ml)	50% at 17.13 μg/mL	10.1371/journal.pone.0040135
1466	Peptide BmKb1, Non-disulfide-bridged peptide 4.2, NDBP-4.2, Toxin peptide 6, MeuFSPL-1	FLFSLIPSAISGLISAFK-NH_2	18	*S. aureus* CGMCC 1.89 (MBC 5.27 μM)	MRBCs (61±2.5% at 3.12 μM)	10.3389/fmicb.2018.00320
2144	Meucin-18, Venom antimicrobial peptide-9	FFGHLFKLATKIIPSLFQ	18	*S. aureus* CGMCC 1.89 (MBC 0.87 μM)	MRBCs (100% at 12.5 μM)	10.3389/fmicb.2018.00320
2159	Cytotoxic linear peptide IsCT	ILGKIWEGIKSLF-NH_2	13	*S. aureus* KCTC 1621 (2 μM)	8% at 10 μM	10.1016/j.bbrc.2004.08.144
2160	Cytotoxic linear peptide IsCT [WA6]	ILGKIAEGIKSLF-NH_2	13	*S. aureus* KCTC 1621 (>64 μM)	Not active at 100 μM	10.1016/j.bbrc.2004.08.144
2161	Cytotoxic linear peptide IsCT [WL6]	ILGKILEGIKSLF-NH_2	13	*S. aureus* KCTC 1621 (4 μM)	16%	10.1016/j.bbrc.2004.08.144
2162	Cytotoxic linear peptide IsCT [EK7]	ILGKIWKGIKSLF-NH_2	13	*S. aureus* KCTC 1621 (1μM)	8% at 25 μM	10.1016/j.bbrc.2004.08.144
2163	Cytotoxic linear peptide IsCT [WL6, SK11]	ILGKILKGIKKLF-NH_2	13	*S. aureus* KCTC 1621 (2 μM)	5% at 50 μM	10.1016/j.bbrc.2004.08.144
2164	Cytotoxic linear peptide IsCT [EK7, GP8, SK11]	ILGKIWKPIKKLF-NH_2	13	*S. aureus* CCARM 3543 (0.5 μM) MRSA	Not active at 100 μM	10.1016/j.bbrc.2004.08.144
3246	Cytotoxic linear peptide IsCT2f	IFGAIWNGIKS	11	Not active at 100 μM	Not active at 100 μM (SRBCs)	10.1016/S0006-291X(02)00423-0
3247	Cytotoxic linear peptide IsCT2	IFGAIWNGIKSLF-NH_2	13	*S. aureus* ATCC 25293 (0.7 μM)	SRBCs (0% at 25 μM)	10.1016/S0006-291X(02)00423-0
3248	Cytotoxic linear peptide IsCTf	ILGKIWEGIKS	11	Not active at 100 μM	Not active at 100 μM (SRBCs)	10.1016/S0006-291X(02)00423-0
3343	Mastoparan-L	INLKALAALAKKIL-NH_2	14	*S. aureus* ATCC 292136.3 (12.5 μM)	10% at 100 μM	10.1046/j.1432-1033.2002.03177.x
3353	Peptide Hp1090, Um5	IFKAIWSGIKSLF-NH_2	13	*S. aureus* DSM 2569 Not active at 250 μM	PRBCs (10% at 11.944 μM)	10.3390/toxins9010022
3354	Peptide Hp1035	IFSAIGGFLKSIF-NH_2	13	Hepatitis C virus (HCV) Not active	—	10.1016/j.peptides.2010.10.008
3475	Amphiphatic peptide CT1, VmCT1	FLGALWNVAKSVF-NH_2	13	*S. aureus* ATCC 25923 (10 μM)	12% at 50 μM	10.1016/j.peptides.2012.02.002
3476	Amphiphatic peptide CT2, VmCT2	FLSTLWNAAKSIF-NH_2	13	*S. aureus* ATCC 25923 (10 μM)	84% at 50 μM	10.1016/j.peptides.2012.02.002
3477	Amphipathic peptide CT1, VsCT1	FLKGIIDTVSNWL-NH_2	13	*S. aureus* ATCC 25923 Not active at 50 μM	6% at 50 μM	10.1016/j.peptides.2012.02.002
3478	Amphipathic peptide CT2, VsCT2	FLKGIIDTVSKLF-NH_2	13	*S. aureus* ATCC 25923 Not active at 50 μM	2% 50 μM	10.1016/j.peptides.2012.02.002
3479	Antimicrobial peptide CT1-NDBP-5.17, UyCT1	GFWGKLWEGVKNAI-NH_2	14	*S. aureus* ATCC 25923 (15 μM)	26% at 15 μM	10.1016/j.toxicon.2012.11.017
3480	Antimicrobial peptide CT1-NDBP-5.17, UyCT2	FWGKLWEGVKNAI-NH_2	13	*S. aureus* ATCC 25923 Not active at 100 μM	7% at 25 μM	10.1016/j.toxicon.2012.11.017
3481	CT3-NDBP-5.15, UyCT3, OcyC1, NDBP-5.7	ILSAIWSGIKSLF-NH_2	13	*S. aureus* ATCC 25923 (10 μM)	20% at 10 μM	10.1016/j.toxicon.2012.11.017
3482	Antimicrobial peptide CT5-NDBP-5.16, UyCT5	IWSAIWSGIKGLL-NH_2	13	*S. aureus* ATCC 25923 (1 μM)	0% at 2 μM	10.1016/j.toxicon.2012.11.017
3489	Pantinin-2	IFGAIWKGISSLL-NH_2	13	*S. aureus* AB94004 (48 μM)	8% at 16 μM	10.1016/j.peptides.2013.03.026
3490	Pantinin-1	GILGKLWEGFKSIV-NH_2	14	*S. aureus* AB94004 (8 μM)	21% at 64 μM	10.1016/j.peptides.2013.03.026
3491	Pantinin-3	FLSTIWNGIKSLL-NH_2	13	*S. aureus* AB94004 (16 μM)	70% at 16 μM	10.1016/j.peptides.2013.03.026
3599	Amphipathic peptide CT1	GFWGSLWEGVKSVV-NH_2	14	*S. aureus* AB 94004 (12.5 μg/mL)	ND	10.1016/j.peptides.2009.10.008
3615	Amphipathic peptide CT2, Um3	GFWGKLWEGVKSAI-NH_2	14	*S. aureus* AB94004 (6.25μg/mL)	50% at 80.3 μg/mL	10.1016/j.peptides.2012.04.010
3752	Mucroporin	LFGLIPSLIGGLVSAFK-NH_2	17	*S. aureus* AB 94004 (25 μg/mL)	ND	10.1128/AAC.00542-08
3753	Mucroporin-M1, Mucroporin [G3,11R, P6K, G10K]	LFRLIKSLIKRLVSAFK-NH_2	17	*S. aureus* AB94004 (5 μg/mL)	—	10.1128/AAC.00542-08
3754	Imcroporin	FFSLLPSLIGGLVSAIK-NH_2	17	*S. aureus* AB94004 (20 μg/mL)	—	10.1128/AAC.01436-08
3884	Antimicrobial peptide 1, AamAP1	FLFSLIPHAIGGLISAFK-NH_2	18	*S. aureus* NCTC 10788 (20 μM)	100% at 120 μM	10.1016/j.peptides.2012.03.016
3885	Antimicrobial peptide 2, AamAP2	FPFSLIPHAIGGLISAIK-NH_2	18	*S. aureus* NCTC 10788 (20 μM)	100% at 100 μM	10.1016/j.peptides.2012.03.016
3935	Ctriporin	FLWGLIPGAISAVTSLIKK-NH_2	19	*S. aureus* AB94004 (5 μg/mL)	10% at 30 μg/mL	10.1128/AAC.00369-11

						10.1016/j.micpath.2021.104960
4297	TsAP-1	FLSLIPSLVGGSISAFK-NH_2	17	*S. aureus* NCTC 10788 (120 μM)	6.48% at 160 μM	10.1016/j.biochi.2013.06.003
4298	TsAP2	FLGMIPGLIGGLISAFK-NH_2	17	*S. aureus* NCTC 10788 (5 μM)	100% at 80 μM	10.1016/j.biochi.2013.06.003
4299	TsAP-1 [S7K] [G10K][G11K][S12I][S14K]	FLSLIPKLVKKIIKAFK	17	*S. aureus* NCTC 10788 (2.5 μM)	EqRBCs (28% at 5 μM)	10.1016/j.biochi.2013.06.003
4300	TsAP-2 [G7K] [G10K] [G11K] [S14K]	FLGMIPKLIKKLIKAFK	17	*S. aureus* NCTC 10788 (5 μM)	EqRBCs (28% at 5 μM)	10.1016/j.biochi.2013.06.003
4330	Peptide Hp1036	ILGKIWEGIKSIF-NH_2	13	HSV-1 (IC_{50} 0.43±0.09 μM) inhibition of the initial infection	50% at 34.91±0.47 μM	10.1016/j.antiviral.2013.11.013
4331	Peptide Hp1239	ILSYLWNGIKSIF-NH_2	13	HSV-1 (IC_{50} 0.41±0.06 μM) inhibition of the initial infection	50% at 33.32 ± 0.96 μM	10.1016/j.antiviral.2013.11.013
4572	Kn2-7	FIKRIARLLRKIF-NH_2	13	*S. aureus* AB94004 (3.13 μg/mL	50% 90.27 μg/mL	10.1371/journal.pone.0040135
7227	AamAP1 [S4K, H8K, G11, 12K, A16K]	FLFKLIPKAIKKLISKFK	18	*S. aureus* ATCC 29213 (5 μM)	0% at 5 μM	10.3390/ph7050502
8151	AaeAP1	FLFSLIPSVIAGLVSAIRN-NH_2	19	*S. aureus* NTCC 10788 (4 μM)	100% at 32 μM	10.3390/toxins7020219
8152	AaeAP2	FLFSLIPSAIAGLVSAIRN-NH_2	19	*S. aureus* NCTC 10788 (16 μg/mL)	EqRBCs (100% at 64 μg/mL)	10.3390/toxins7020219
8153	AaeAP1 [S4,8,15K; A11K, N19K]	FLFKLIPKVIKGLVKAIRK-NH_2	19	*S. aureus* NCTC 10788 (4 μg/mL)	EqRBCs (100% at 32 μg/mL)	10.3390/toxins7020219
8154	AaeAP2 [S4,8,15K; A11K, N19K]	FLFKLIPKAIKGLVKAIRK-NH_2	19	*S. aureus* NCTC 10788 (4 μg/mL)	EqRBCs (100% 64 μg/mL)	10.3390/toxins7020219
8199	Stigmurin	FFSLIPSLVGGLISAFK-NH_2	17	*S. aureus* ATCC 29213 (8.68 μM)	20% at 139.5 μM	10.1016/j.peptides.2015.03.003
8437	VpAmp1.0	LPFFLLSLIPSAISAIKKI-NH_2	19	*S. aureus* ATCC 25923 (2.5 μM)	50% at 9.2 μM	10.1016/j.peptides.2015.08.014
8438	VpAmp1.1	FFLLSLIPSAISAIKKI-NH_2	17	*S. aureus* ATCC 25923 (5 μM)	50% 33.7±2.4 μM	10.1016/j.peptides.2015.08.014
8864	Hp1404	GILGKLWEGVKSIF-NH_2	14	*S. aureus* ATCC 25923 (6.25 μg/mL)	10% at 100 μg/mL	10.1371/journal.pone.0097539
9867	ToAP3, Im-4	FIGMIPGLIGGLISAIK-NH_2	17	*S. aureus* NBRC 13276 (5-10 μM)	SRBCs (50% at >30 μM)	10.1016/j.toxicon.2017.09.010
9868	NDBP-4.23, TsAP-2, TcAP clone 4, Tbah00286	FLGMIPGLIGGLISAFK-NH_2	17	*C. albicans* SC5314 (50 μM)	48% 100 μM	10.3389/fmicb.2016.01844
9869	ToAP1	FIGMIPGLIGGLISAFK-NH_2	17	*C. albicans* SC5314 (50 μM)	48% at 100 μM	10.3389/fmicb.2016.01844
9870	Amphipathic peptide OcyC2, NDBP-5.8	GILGKIWEGVKSLI	14	*C. albicans* SC5314 (100 μM)	—	10.3389/fmicb.2016.01844
9945	Uy17	ILSAIWSGIKGLL-NH_2	13	*S. aureus* ATCC 25923 (MBC 23.2 μM)	<5% at 380 μM	10.1371/journal.pone.0222438
9946	Uy192	FLSTIWNGIKGLL-NH_2	13	*S. aureus* ATCC 25923 (MBC 42.4 μM)	<5% at 380 μM	10.1371/journal.pone.0222438
9947	Uy234	FPFLLSLIPSAISAIKRL-NH_2	18	*S. aureus* ATCC 25923 (MBC 29.6±25 μM)	25% at 370 μM	10.1371/journal.pone.0222438
9951	Um2	ISQSDAILSAIWSGIKSLF-NH_2	19	*S. aureus* DSM 2569 Not active at 250 μM	PRBCs (10% at 2.36 μM)	10.3390/toxins9010022
9952	Um4	FFSALLSGIKSLF-NH_2	13	*S. aureus* DSM2569 (15 μM)	9% at 100 μM	10.3390/toxins9010022
9953	UyCT3 [L2F, S3G], D1	IFGAIWSGIKSLF-NH_2	13	*S. aureus* ATCC 25923 (MBC 29.6±25 μM)	25% at 370 μM	10.3390/toxins9010022
9954	Uy192 [G11S, L13F], D2	FLSTIWNGIKSLF-NH_2	13	*S. aureus* DSM 2569 (8 μM)	PRBCs (10% at 2.94 μM)	10.3390/toxins9010022
9955	UyCT1 [E8K, G9P, N12K], D4	GFWGKLWKPVKKAI-NH_2	14	*S. aureus* DSM 2569 Not active at 250 μM	PRBCs (Not active at 100 μM)	10.3390/toxins9010022
9956	UyCT1 [W7L, N12K], D5	GFWGKLLEGVKKAI-NH_2	14	*S. aureus* DSM 2569 Not active at 250 μM	PRBCs (10% at 110.86 μM)	10.3390/toxins9010022
9957	UyCT1 - 3K, D11	GFWGKLWEGVKNAIKKK-NH_2	17	*S. aureus* DSM 2569 Not active at 250 μM	PRBCs (10% at 39.76 μM)	10.3390/toxins9010022
10158	Non-disulfide-bridged peptide 5.5, NDBP-5.5	IFSAIAGLLSNLL-NH_2	13	*Mycobacterium abscessus* ssp. *massiliense* (MBC 200 μM)	10% at 611.8 μM	10.3389/fmicb.2017.00273
10462	IsCT1 [I5,9A]	ILGKAWEGAKSLF-NH_2	13	*S. aureus* ATCC 29213 (>100 μg/mL)	10% at 100 μg/mL	10.3390/antibiotics6030013
10463	IsCT1 [I5,9V]	ILGKVWEGVKSLF-NH_2	13	*S. aureus* ATCC 29213 (>100 μg/mL)	8% at 100 μg/mL	10.3390/antibiotics6030013

10464	IsCT1 [I5,9L]	ILGKLWEGLKSLF-NH_2	13	*S. aureus* ATCC 29213 (50 μg/mL)	80% at 50 μg/mL	10.3390/antibiotics6030013
10465	IsCT1 [K10E]	ILGKIWEGIESLF-NH_2	13	*S. aureus* ATCC 29213 (>100 μg/mL)	0% at 100 μg/mL	10.3390/antibiotics6030013
10466	IsCT2 [F2L; I5,9A]	ILGAAWNGAKSLF-NH_2	13	*S. aureus* ATCC 29213 (>100 μg/mL)	5% at 100 μg/mL	10.3390/antibiotics6030013
10467	IsCT2 [F2L; I5,9V]	ILGAVWNGVKSLF-NH_2	13	*S. aureus* ATCC 29213 (>100 μg/mL)	18% at 100 μg/mL	10.3390/antibiotics6030013
11211	MeuFSPL-2	FLFSLIPSAISGLINAFK-NH_2	18	*S. aureus* CGMCC 1.89 (LC 3.14 μM)	MRBCs (100% at 12.5 μM)	10.3389/fmicb.2018.00320
11223	Spiniferin	ILGEIWKGIKDIL-NH_2	13	*S. aureus* AB 94004 (> 82 μM)	Not active at 48μM	10.1016/j.peptides.2013.12.012
11224	Spiniferin [E4K, D11N]	ILGKIWKGIKNIL-NH_2	13	*S. aureus* AB94004 (12 μM)	1.7% at 6 μM	10.1016/j.peptides.2013.12.012
11270	Stigmurin [S7K, G10K], StigA6	FFSLIPKLVKGLISAFK-NH_2	17	*S. aureus* ATCC 29213 (2.34 μM)	40% at 75 μM	10.3390/toxins10040161
11271	Stigmurin [S3,7K; G10K], StigA16	FFKLIPKLVKGLISAFK-NH_2	17	*S. aureus* ATCC 29213 (2.34 μM)	30% at 75 μM	10.3390/toxins10040161
12239	HAP-1 (1-19)	QKDDEEESRFFFNFIFSAE-NH_2	19	*S. aureus* AB94004 (not active at 80 μM)	not active at 80 μM	10.3390/molecules23123314
12417	Stigmurin [G10,11K; S14K], StigA25	FFSLIPSLVKKLIKAFK-NH_2	17	*S. aureus* ATCC 29213 (1.2 μM)	18.5% at 9.4 μM	10.3390/ijms20030623
12418	Stigmurin [S3,6,14K; G10,11K], StigA31	FFKLIPKLVKKLIKAFK-NH_2	17	*S. aureus* ATCC 29213 (2.3 μM)	11.2% at 9.4 μM	10.3390/ijms20030623
12573	Antimicrobial peptide 1, AamAP1[P7R; H8K]	FLFSLIRKAIGGLISAFK	18	*S. aureus* ATCC 29213 (5 μM)	5.1% at 10 μM	10.3390/molecules23071603
13647	AcrAP1, AP1-Z1	FLFSLIPHAISGLISAFK-NH_2	18	*S. aureus* NCTC 10788 (8 μM)	EqRBCs (100% at 64 μM)	10.7150/ijbs.9859
13648	AcrAP1 [S4K, H8K,S11K,S15K]	FLFKLIPKAIKGLIKAFK-NH_2	18	*S. aureus* NCTC 10788 (4 μM) (MBC 32 μM)	EqRBCs (100% at 32 μM)	10.1016/j.bbrc.2018.09.095
13649	AcrAP2	FLFSLIPNAISGLLSAFK-NH_2	18	*S. aureus* NCTC 10788 (8 μM) (MBC 32 μM)	EqRBCs (100% at 64 μM)	10.7150/ijbs.9859
13650	AcrAP2 [S4K, N8K,S11K,S15K]	FLFKLIPKAIKGLLKAFK-NH_2	18	*S. aureus* NCTC 10788 (4 μM) (MBC 32 μM)	EqRBCs (100% at 32 μM)	10.7150/ijbs.9859
14497	QnCs-Buap	FFSLIPSLISGLI-NH_2	13	*S. aureus* ATCC 25923 (MBC >353.1 μM)	<5% at 380 μM	10.1371/journal.pone.0222438
14624	Marcin-18	FFGHLFKLATKIIPSLFR	18	*S. aureus* P1389 (2.9 μM)	—	10.3389/fmicb.2018.01159
14625	Megicin-18	FFGALFKLATKIIPSLFR	18	*S. aureus* P1389 (1.5 μM)	—	10.3389/fmicb.2018.01159
14626	VmCT1 [G3R]	FLRALWNVAKSVF-NH_2	13	*S. aureus* ATCC 29213 (1.6 μM)	0% at 1.6 μM	10.1016/j.bioorg.2019.103038
14627	VmCT1 [N7R]	FLGALWRVAKSVF-NH_2	13	*S. aureus* ATCC 29213 (1.6 μM)	0% at 3.1 μM	10.1016/j.bioorg.2019.103038
14634	VmCT1 [S11R]	FLGALWNVAKRVF-NH_2	13	*S. aureus* ATCC 29213 (3.1 μM)	0% at 3.1 μM	10.1016/j.bioorg.2019.103038
14635	VmCT1 [F1G]	GLGALWNVAKSVF-NH_2	13	*E. coli* SBS 363 (50 μM)	0% at 50 μM	10.1016/j.bioorg.2019.103038
14636	VmCT1 [V8P]	FLGALWNPAKSVF-NH_2	13	*E. coli* SBS 363 (50 μM)	0% at 50 μM	10.1016/j.bioorg.2019.103038
14637	VmCT1 [A9L]	FLGALWNVLKSVF-NH_2	13	*S. aureus* ATCC 29213 (0.8 μM)	0% at 1.6 μM	10.1016/j.bioorg.2019.103038
14638	VmCT1 [A9F]	FLGALWNVFKSVF-NH_2	13	*S. aureus* ATCC 29213 (0.8 μM)	0% at 0.8 μM	10.1016/j.bioorg.2019.103038
14639	VmCT1 [V12L]	FLGALWNVAKSLF-NH_2	13	*S. aureus* ATCC 29213 (0.8 μM)	0% at 3.1 μM	10.1016/j.bioorg.2019.103038
14640	VmCT1 [V12Y]	FLGALWNVAKSYF-NH_2	13	*S. aureus* ATCC 29213 (3.1 μM)	0% at 6.3 μM	10.1016/j.bioorg.2019.103038
15179	Mucroporin (7-17)	SLIGGLVSAFK-NH_2	11	No virucidal Activity	—	10.1016/j.peptides.2011.05.015
15558	Eval418	LWGEIWNTVKGLI-NH_2	13	HSV-1 (IC_{50} 2.48 μg/mL)	VCs (50% toxicity at 68.50 μg/mL)	10.7150/thno.21425
15559	Eval418-FH2	LWGHIWNFVHGLI-NH_2	13	HSV-1 (IC_{50} 1.50 μg/mL)	VCs (50% toxicity at 27.60 μg/mL)	10.7150/thno.21425
15560	Eval418-FH3	LWHHIWNFVHGLI-NH_2	13	HSV-1 ((IC_{50} 1.01 μg/mL)	VCs (50% toxicity at 26.83 μg/mL)	10.7150/thno.21425
15561	Eval418-FH4	LWHHIWNTVHHLI-NH_2	13	HSV-1 (IC_{50} 0.87 μg/mL)	VCs (50% toxicity at 27.58 μg/mL)	10.7150/thno.21425
15562	Eval418-FH5	LWHHIWHTVHHLI-NH_2	13	HSV-1 (IC_{50} 0.86 μg/mL)	VCs (50% toxicity at 106.7 μg/mL)	10.7150/thno.21425
16149	MK049518	FLGLLGSVLGSVLPSIFK-NH_2	18	*S. aureus* AB94004 (12.5 μg/mL)	—	10.1016/j.toxicon.2020.07.028
16150	MK049518 [S7,11,15K]	FLGLLGKVLGKVLPKIFK-NH_2	18	*S. aureus* AB94004 (3.13 μg/mL)	HHCs (90% cell death 12.5 μg/mL)	10.1016/j.toxicon.2020.07.028
16151	MK049518 [G3,6,10K; S7,11,15K]	FLKLLKKVLKKVLPKIFK-NH_2	18	*S. aureus* AB94004 (3.13 μg/mL)	HHCs (25% cell death 12.5 μg/mL)	10.1016/j.toxicon.2020.07.028
16788	VmCT1 [F1K]	KLGALWNVAKSVF-NH_2	13	*S. aureus* ATCC 29213 (50 μM)	<5% at 12.5 μM	10.1016/j.ejps.2019.06.006
16789	VmCT1 [A9K]	FLGALWNVKKSVF-NH_2	13	*S. aureus* ATCC 29213 (>50 μM)	<5% at >100 μM	10.1016/j.ejps.2019.06.006
16790	VmCT1 [F1K, V12K]	KLGALWNVAKSKF-NH_2	13	*S. aureus* ATCC 29213 (>50 μM)	<5% at >100 μM	10.1016/j.ejps.2019.06.006
16791	VmCT1 [G3K, N7K]	FLKALWKVAKSVF-NH_2	13	*S. aureus* ATCC 29213 (0.8 μM)	<5% at 1.6 μM	10.1016/j.ejps.2019.06.006
16792	VmCT1 [G3K, S11K]	FLKALWNVAKKVF-NH_2	13	*S. aureus* ATCC 29213 (0.8 μM)	<5% at 3.1 μM	10.1016/j.ejps.2019.06.006

16793	VmCT1 [N7K, S11K]	FLGALWKVAKKVF-NH_2	13	*S. aureus* ATCC 29213 (0.8 μM)	<5% at 3.1 μM	10.1016/j.ejps.2019.06.006
16794	VmCT1 [G3K, N7K, S11K]	FLKALWKVAKKVF-NH_2	13	*S. aureus* ATCC 29213 (0.8 μM)	<5% at 3.1 μM	10.1016/j.ejps.2019.06.006
17527	Im-6	FFFLPSLIGGLVSAIK-NH_2	16	*S. aureus* (5-10 μM)	84% at > 30 μM	10.1016/j.toxicon.2017.09.010
18163	VpCT1	FWSTLLSIGKSLL-NH_2	13	*S. aureus* ATCC 25923 (4.7 μM)	50% at 10.5±0.4 μM	10.1016/j.peptides.2021.170553
18164	VpCT2	FWSTIWNAAKSLI-NH_2	13	*S. aureus* ATCC 25923 (12.5 μM)	50% at 10.8±0.4 μM	10.1016/j.peptides.2021.170553
18165	VpCT3	FLQGIIDTVGKWL-NH_2	13	*S. aureus* ATCC 25923 (>100 μM)	50% at 83.7±1.8 μM	10.1016/j.peptides.2021.170553
18166	VpCT3 [I6W]	FLQGIWDTVGKWL-NH_2	13	*S. aureus* ATCC 25923 (>100 μM)	50% at 37.9±0.4 μM	10.1016/j.peptides.2021.170553
18167	VpCT4	LWGALLGLGSTLLSKL-NH_2	16	*S. aureus* ATCC 25923 (9.3 μM)	50% at 4.8±0.7 μM	10.1016/j.peptides.2021.170553
18168	VpCTConsensus	FLSKIWDGVKSLL-NH_2	13	*S. aureus* ATCC 25923 (37.5 μM)	50% at 39.9±0.4 μM	10.1016/j.peptides.2021.170553
18292	Peptide Ctri9594	GVVDTLKNLLMGLL-NH_2	14	*S. aureus* AB94004 (25 μg/mL)	—	10.3390/antibiotics10080896
18735	Checacin1 (1-11)	FFGAIAKLAMK	11	*S. aureus* ATCC 33592 (>50 μM)	CKCs (not active at 100 μM)	10.3390/toxins14010058
18736	Checacin1 (12-25)	FLPAIYKQIQKKRK-NH_2	14	*S. aureus* ATCC 33592 (>50 μM)	CKCs (not active at 100 μM)	10.3390/toxins14010058
20289	IsCT [E7P]	ILGKIWPGIKSLF-NH_2	13	*S. aureus* ATCC 12600 (64 μM)	<5% at 128 μM	10.1021/acsinfecdis.1c00261
20290	IsCT [G3K, G8P]	ILKKIWEPIKSLF-NH_2	13	*S. aureus* ATCC 12600 (>128 μM)	<5% at 128 μM	10.1021/acsinfecdis.1c00261
20291	IsCT [I1A; G3,8K; I5F]	ALKKFWEKIKSLF-NH_2	13	*S. aureus* ATCC 12600 (8 μg/mL)	<5% at 32 μM	10.1021/acsinfecdis.1c00261
20292	IsCT [I1A, I5F, E7P, G8K]	ALGKFWPKIKSLF-NH_2	13	*S. aureus* ATCC 12600 (>128 μM)	<5% 128 μM	10.1021/acsinfecdis.1c00261
20293	IsCT [G3K,E7K,I9K]	ILKKIWKGKKSLF-NH_2	13	*S. aureus* ATCC 12600 (>128 μM)	<5% at 128 μM	10.1021/acsinfecdis.1c00261
20294	IsCT [G3K, E7K, G8P, I9K]	ILKKIWKPKKSLF-NH_2	13	*S. aureus* ATCC 12600 (>128 μM)	<5% at 128 μM	10.1021/acsinfecdis.1c00261
21142	Hp1470	IFKAIWSGINRLF	13	*S. aureus* AB94004 (6.25 μg/mL)	—	10.1016/j.toxicon.2023.107189
21411	TtAP-2	IFGMIPGLIGGLISAFK-NH_2	17	*S. aureus* ATCC 43300 (25 μg/mL)	50% at 31 μg/mL	10.3390/antibiotics12091404

[a] Database of Antimicrobial Activity and Structure of Peptides (DBAASPR)

[b] Data obtained in human red blood cells or: **CKC:** Madin-Darby canine kidney cells; **EqRBCs:** Horse erythrocytes; **HHCs:** Human hepatocyte cells; **MBC:** Minimal Bactericidal Concentration; **MRBCs:** Mice red blood cells; **ND:** Not determined; **PRBCs:** Pig red blood cells; **SRBCs:** Sheep erythrocytes; **VCs:** Vero cells